Objectives: The live vaccine strain TAD Salmonella vacT (vacT) carrying gyrA mutations W59R, G75A, D87G and A866S shows resistance to nalidixic acid and rifampicin, but increased susceptibility to macrolides, fluoroquinolones and phenylalanyl-arginyl-b-naphthylamide. This phenotype contrasts with the presence of the gyrA mutation D87G usually associated with reduced susceptibility to fluoroquinolones. Thus, a possible compensatory effect on the suppression of gyrA-mediated resistance by gyrA mutations within the quinolone resistance-determining region alone or in combination (intragenic) or by a mutation affecting AcrAB-TolC (extragenic), the major multidrug resistance efflux pump in Salmonella, was investigated.
Introduction
Salmonella Typhimurium strain 'TAD Salmonella vacT' (vacT; Lohmann Animal Health Cuxhaven, Germany) is an attenuated live vaccine strain licensed for use in chicken. It shows reduced susceptibilities to rifampicin and nalidixic acid, and increased susceptibilities to macrolides and fluoroquinolones, e.g. sparfloxacin. Compared with the parent strain M415, the gyrA gene of vacT has three novel mutations, W59R, G75A and A866S, in addition to the D87G mutation. No mutations in other fluoroquinolone target genes (gyrB, parC and parE) had been found. 1 The increased fluoroquinolone susceptibility of vacT contrasts with the presence of the gyrA mutation D87G, which is usually associated with fluoroquinolone resistance. 2 Therefore, a possible explanation could be a compensatory mutation, either intragenic by novel gyrA mutations, which might be detectable by altered supercoiling activity, or extragenic by a mutation increasing the drug concentration in the cell. The latter can be achieved either by increased influx resulting from overexpression of outer membrane porin OmpF 3 or by reduced drug export through unspecific multiple drug resistance (MDR) efflux pumps like AcrAB-TolC, which is described as the major efflux pump in Salmonella spp. 4 Deletions in corresponding genes acrB and tolC have been described as causing hypersusceptibility to antibiotics including fluoroquinolones. 4 -6 Furthermore, a role of the AcrAB-TolC efflux pump in the virulence of Salmonella spp. is discussed. The present study aimed at understanding the molecular basis for the fluoroquinolone-susceptible phenotype of vacT.
Materials and methods

Bacterial strains and plasmids
Strains used in this study are summarized in Table 1 . Plasmids used include: for homologous recombination, pKD4 (kan), 8 pKOV (sacB) 9 and pCP20; 8 for gyrA complementation tests, pBP507 (control) 2 and pBP517 (Escherichia coli gyrA þ ); 2 for acrB complementation tests, pPHB861 (derivate of vector pBAD18) 10 bearing the wild-type acrAB genes of E. coli under the control of the paraC promoter; and for determining the degree of DNA supercoiling, pPHB90 and pPHB91 (luciferase reporter gene plasmids). 
In vitro mutagenesis by homologous recombination
Defined gyrA mutants were generated in vitro by site-specific integration of point mutations into the chromosomal gyrA gene of M415. For the selection of novel combinations of gyrA mutations with unknown resistance phenotypes, the gyrA fragments carrying different point mutations were inserted by homologous recombination together with a kanamycin resistance cassette (kan). The fusion between the gyrA fragment and kan (amplified from vector pKD4 together with FRT sites required for subsequent elimination of the cassette by a flippase that is expressed from vector pCP20) 8 was obtained by splicing of overlap extension (SOEing) PCR. The fusion products flanked by homologous sequences for recombination into M415 were cloned into vector pKOV carrying a temperaturesensitive origin, a cat gene mediating chloramphenicol resistance and the sacB gene. 9 Homologous recombination was performed as described previously. 9 Successful integration of the kanamycin resistance cassette was verified by PCR. Integration of gyrA mutations was confirmed by an 'amplification refractory mutation system PCR' (ARMS-PCR) based on match or mismatch of the reverse primer with a polymorphic DNA sequence. Elimination of kan was performed as described previously. 8 The primers used for DNA sequence analysis, PCR and ARMS-PCR are listed in Table S1 [available as Supplementary data at JAC Online (http://jac. oxfordjournals.org/)].
Investigation of gyrA mutants
Resulting recombinant Salmonella strains were characterized by their susceptibilities to various fluoroquinolones determined as MICs with the broth microdilution test. 1 The effects of the different gyrA point mutations on the fluoroquinolone susceptibilities of the different recombinant strains were investigated in a complementation assay using either plasmid pBP507 or pBP517. 2 The degree of DNA supercoiling was determined using a pair of luciferase-based reporter gene plasmids pPHB90 and pPHB91 to detect a possible impact of the novel mutation(s) on the supercoiling activity of the mutant enzyme as described previously. Single-step gyrA mutant SM415-87 (D87Y) selected in vitro from M415 with ciprofloxacin was used as a control strain.
Sequence analysis of acrRAB genes and complementation assay
The genes acrR, acrA and acrB of M415 and vacT were sequenced using the conditions described previously.
1 acrB complementation assays were performed by transforming vacT and M415 with plasmid pPHB861 bearing a wild-type allele of acrAB of E. coli.
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Results and discussion
Intragenic compensation: role of novel gyrA mutations
Further analysis focused on those three gyrA mutations (W59R, G75A and D87G) within the quinolone-resistance determining region (QRDR) by introducing them, alone and in combination, into the chromosomal gyrA gene of M415 using homologous recombination. The resulting three recombinant gyrA mutants RM415-87, RM415-59-87 and RM415-75-87 (Table 1) as well as the in vitro selected mutant SM415-87 carrying gyrA mutation D87Y were further characterized ( Table 1) . Except for vacT, all mutants carrying a gyrA mutation at codon 87 showed increased MICs of ciprofloxacin and sparfloxacin. Compared with the gyrA mutant RM415-87, mutation G75A (RM415-75-87) had no effect on the quinolone susceptibility, while mutation W59R (RM415-59-87) was associated with 2-to 4-fold lower MICs of ciprofloxacin, nalidixic acid and sparfloxacin. MICs for both double mutants remained above those of vacT (Table 1 ). This argues against gyrA mutations as the sole cause of the higher susceptibility to some fluoroquinolones of vacT (e.g. sparfloxacin, Table 1 ). Introducing a plasmid-encoded wild-type gyrA gene into the generated gyrA mutants reduced MICs of quinolones to the wildtype level, but to a lower level for vacT. This indicates that a gyrA mutation affecting D87 decreases the fluoroquinolone susceptibilities irrespective of the presence of novel gyrA mutations either at residue 59 or 75 or a combination of all three mutations as in vacT. Instead, it argues for an additional mechanism causing an increased susceptibility to sparfloxacin and erythromycin like reduced efflux. The high susceptibility of vacT to sparfloxacin compared with ciprofloxacin and nalidixic acid can be explained by either differing substrate affinities of AcrAB-TolC for sparfloxacin . ciprofloxacin . nalidixic acid or different membrane permeabilities. The lower quinolone MICs for vacT compared with M415 in the presence of a complementing gyrA þ allele argue for a decreased MDR efflux (Table 1) .
Moreover, the reduced degree of global DNA supercoiling to 55-60% that of wild-type M415 for gyrA mutants carrying D87G, but not D87Y, irrespective of the presence of an additional gyrA mutation (Table 1 ) supports the idea that the two novel mutations in the QRDR are of minor importance for the gyrA function. A corresponding effect of the gyrA mutation D87G had been described previously in E. coli.
11 A reduced supercoiling degree could result in altered gene expression and, subsequently, prolonged generation time and attenuation of vacT. 1 Together these results argue against an intragenic compensatory effect of the novel gyrA mutations on fluoroquinolone susceptibility.
Extragenic compensation: role of the AcrAB efflux pump
Hypersusceptibility to sparfloxacin and erythromycin and increased susceptibility to an efflux pump inhibitor support the idea of a reduced active efflux in vacT. 1 DNA sequence analysis of genes acrRAB of M415 and vacT revealed two deletions in the acrB gene of vacT: a 6 bp deletion at codons T302, A303 and T304 (numbering according to M415) restoring the reading frame and a 10 bp deletion at codons L876, Y877, A878 and I879 resulting in a frameshift and a premature translational stop at amino acid 876 of the AcrB protein in vacT. The first deletion in acrB located in the pore domain deletes amino acids 302 and 303 whose role is as yet unknown, while the second deletion located between transmembrane domains TM10 and TM11 ( Figure 1 ) deletes 5 of a total of 12 transmembrane a-helices per monomer including amino acids K940 and T978 that appear to play an essential role in proton translocation. 12, 13 This is likely to impair the normal function of AcrB. To further support this hypothesis, a complementation assay was performed (Table 1) by introducing a plasmid-encoded wild-type allele of acrB from E. coli (acrB þ ) into vacT and into parent M415 as the control for a possible gene dose effect and to avoid effects due to overexpression of the pump.
The MICs of fluoroquinolones and macrolides for M415 were unaffected by the plasmid-coded acrB þ gene but were increased for vacT (Table 1) . These results point to a non-functional AcrB efflux pump as the cause for the increased fluoroquinolone susceptibility of vacT (gyrA D87G). 1 The ineffectiveness of topoisomerase mutations to mediate fluoroquinolone resistance in the absence of a functional AcrAB-TolC efflux pump was shown previously. 6 Moreover, Baucheron et al. 7 used tolC and acrB knock-out mutants for colonization studies of Salmonella enterica strains to demonstrate increased susceptibilities of both mutants to bile salts; however, only tolC mutants showed reduced ability to colonize chicken. These data point to a more general role of the TolC porin in combination with MDR efflux pumps, including AcrAB in the pathogenesis of non-typhi Salmonella.
Conclusion
The unexpected fluoroquinolone susceptibility of the Salmonella Typhimurium gyrA mutant (D87G) vacT is due to a deletion mutation in acrB. The reduced degree of DNA supercoiling of vacT is associated with the gyrA D87G mutation. The influence of the acrB deletion(s) on the attenuation of the virulence and presumably the fitness of the live vaccine strain vacT seems plausible.
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Transmembrane domain Figure 1 . Structure of an AcrB trimer as side view of ribbon representation (PDB 1IWG). 12 Three protomers are individually coloured (red, blue and purple). The deleted residues are highlighted in yellow (T302-T304) and green (L876-I879). The region that is lacking due to the premature stop by the frameshift mutation is coloured in grey. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
